What is Mark Sabag’s Teva share ownership after the reported transactions?

Following the March 3, 2026 conversions, Mark Sabag directly held 219,206 ordinary shares of Teva Pharmaceutical Industries. This figure reflects his ownership after the restricted share units vested and were settled into ordinary shares at no exercise price.

What does each Teva restricted share unit entitle Mark Sabag to receive?

Each restricted share unit represents a contingent right to receive, at settlement, either one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share, depending on the company’s chosen settlement method.

Teva (NYSE: TEVA) officer converts RSUs into ordinary shares

Q: What insider transaction did Mark Sabag report at TEVA?

Mark Sabag reported exercises of restricted share units that converted into ordinary shares on March 3, 2026. These were non-cash settlements at $0.00 per share , increasing his directly held ordinary share position in Teva Pharmaceutical Industries.

Q: How many Teva shares did Mark Sabag receive from RSU conversions?

He converted 24,900 and 141,478 restricted share units into the same number of ordinary shares. Each restricted share unit represented a contingent right to receive one ordinary share or its cash value at settlement, as determined by the compensation committee.

Q: How were Mark Sabag’s time-based restricted share units structured at TEVA?

Time-based restricted share units were granted on March 3, 2024 , with 24,900 units vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 units scheduled to vest on March 3, 2027, subject to continued service conditions.

Q: What performance-based RSUs did Mark Sabag earn at Teva?

Certain restricted share units were earned on January 27, 2026 after performance criteria were certified by the Human Resources and Compensation Committee. These units subsequently vested on March 3, 2026 after time-based vesting conditions were satisfied, then settled into ordinary shares.

Q: How can Teva ordinary shares from these RSUs be represented in U.S. markets?

Teva’s ordinary shares may be represented by American Depositary Shares (ADSs) , with each ADS currently representing one ordinary share. This structure allows the underlying ordinary shares acquired from restricted share unit settlements to trade in U.S. markets through ADSs.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Teva Pharmaceutical Industries officer Mark Sabag exercised restricted share units on March 3, 2026, converting 24,900 and 141,478 units into the same number of ordinary shares at $0.00 per share. After these settlements, he directly held 219,206 ordinary shares.

Insider Trade Summary

166,378 shares exercised/converted

Mixed 4 txns

Insider Sabag Mark

Role See "Remarks"

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	24,900	$0.00	--
Exercise	Restricted Share Units	141,478	$0.00	--
Exercise	Ordinary Shares	24,900	$0.00	--
Exercise	Ordinary Shares	141,478	$0.00	--

Holdings After Transaction: Restricted Share Units — 24,901 shares (Direct); Ordinary Shares — 77,728 shares (Direct)

Footnotes (1)

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 3, 2024, with 24,900 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

Form 4 Insider Transactions: What Each Field Means →

03/05/2026 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV

6944020

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	03/03/2026		M		24,900	A	⁽²⁾	77,728	D
Ordinary Shares⁽¹⁾	03/03/2026		M		141,478	A	⁽²⁾	219,206	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽²⁾	03/03/2026		M			24,900	⁽³⁾	⁽³⁾	Ordinary Shares⁽¹⁾	24,900	$0	24,901	D
Restricted Share Units	⁽²⁾	03/03/2026		M			141,478	⁽⁴⁾	⁽⁴⁾	Ordinary Shares⁽¹⁾	141,478	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 3, 2024, with 24,900 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

4. Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Mark Sabag report at TEVA?

Mark Sabag reported exercises of restricted share units that converted into ordinary shares on March 3, 2026. These were non-cash settlements at $0.00 per share, increasing his directly held ordinary share position in Teva Pharmaceutical Industries.

How many Teva shares did Mark Sabag receive from RSU conversions?

He converted 24,900 and 141,478 restricted share units into the same number of ordinary shares. Each restricted share unit represented a contingent right to receive one ordinary share or its cash value at settlement, as determined by the compensation committee.

What performance-based RSUs did Mark Sabag earn at Teva?

Certain restricted share units were earned on January 27, 2026 after performance criteria were certified by the Human Resources and Compensation Committee. These units subsequently vested on March 3, 2026 after time-based vesting conditions were satisfied, then settled into ordinary shares.

How can Teva ordinary shares from these RSUs be represented in U.S. markets?

Teva’s ordinary shares may be represented by American Depositary Shares (ADSs), with each ADS currently representing one ordinary share. This structure allows the underlying ordinary shares acquired from restricted share unit settlements to trade in U.S. markets through ADSs.